Blue Water Life Science Advisors, LP
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Blue Water Life Science Advisors, LP reported 8 stock positions worth $106.3 million. Its top holding was Natera (NTRA) at 43.3% of the portfolio, followed by Akoya Biosciences (AKYA, 20.7%) and Guardant Health (GH, 11.1%). Compared with Q4 2023, it opened 1 new position, sold out of 2, added to 2 and reduced 1. The biggest buy was Natera (NTRA, shares +27%) and the biggest sale an exit from Thermo Fisher Scientific (TMO).
- Most Recent 13F
- Q2 2026
- Location
- LARKSPUR, CA
- CIK
- 0001789778
- Portfolio Value
- $106.3M (Q1 2024)
- SEC Filing
- 0001172661-24-002531 ↗ filed May 15, 2024
Holdings Value
Holdings 8 stocks · $106.3M
| NTRA Natera Inc. | 43.28% | 503,094 | $46.0M | Add +26.6% |
| AKYA Akoya Biosciences Inc. | 20.72% | 4,697,785 | $22.0M | No change |
| GH Guardant Health Inc. | 11.08% | 571,047 | $11.8M | No change |
| TXG 10X Genomics Inc. Class A | 6.87% | 194,500 | $7.3M | No change |
| QTRX Quanterix Corp. | 6.85% | 309,093 | $7.3M | Add +7.3% |
| ADPT Adaptive Biotechnologies | 5.10% | 1,687,665 | $5.4M | No change |
| EXAS Exact Sciences Corp. | 3.72% | 57,343 | $4.0M | New |
| MXCT Maxcyte Inc. | 2.38% | 603,937 | $2.5M | Reduce -68.0% |
Portfolio Sells Q4 2023 → Q1 2024
Portfolio Buys Q4 2023 → Q1 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 9 | $158.8M | CDNA, TXG, PSNL, ADPT, GH |
| Q1 2026 | 10 | $124.7M | TXG, GH, CDNA, ADPT, TWST |
| Q4 2025 | 9 | $159.3M | GH, NTRA, ADPT, PSNL, QTRX |
| Q3 2025 | 7 | $109.6M | ADPT, GH, NTRA, PSNL, CDNA |
| Q2 2025 | 8 | $126.3M | NTRA, ADPT, GH, CDNA, TXG |
| Q1 2025 | 7 | $100.9M | GH, NTRA, ADPT, CDNA, AKYA |
| Q4 2024 | 9 | $112.9M | NTRA, GH, CDNA, ADPT, AKYA |
| Q3 2024 | 8 | $113.7M | NTRA, CDNA, EXAS, AKYA, ADPT |
| Q2 2024 | 8 | $102.8M | NTRA, GH, AKYA, CDNA, TXG |
| Q1 2024 | 8 | $106.3M | NTRA, AKYA, GH, TXG, QTRX |